Analytical Tool - Lung Cancer


April 22, 2013
SKU: BIOS5034159
License type:
Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2013".

According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis’ Taxotere (docetaxel), Bristol-Myers Squibb’s Paraplatin (carboplatin) and Eli Lilly’s Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.

This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.

Find out more about each product by clicking on respective links.

This software application is a searchable database reflects the most recent advances in the field of lung cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.



More Oncology/Hematology reports by BioSeeker Group AB

Wnt Signaling Pathway in Oncology Drug Pipeline Update 2013 by BioSeeker Group AB
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2013Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors ...
Viral Carcinogenesis Drug Pipeline Update 2013 by BioSeeker Group AB
Viral Carcinogenesis Drug Pipeline Update 2013There is a strong association between viruses and the development of human malignancies. We now know that at least six ...
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2013 by BioSeeker Group AB
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2013There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells ...
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2013 by BioSeeker Group AB
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2013Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine that play various roles in a broad spectrum of ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!